Researchers have created monkeys with a precise gene modification, excising two specific genes simultaneously. The technique used to make the modifications, the CRISPR/Cas9 system, could lead to the generation of monkey models of various human diseases.
Until now, gene modification in primates has been unpredictable, relying on the introduction of new genes via engineered viruses. These methods have resulted in genetically engineered monkeys, but researchers have not been able to control the site of gene introduction or the number of copies of the gene. Techniques commonly used in mice rely on recombination events to incorporate introduced genes into embryonic stem cells. This is not feasible for use in primates due, in part, to the animals' long generation times, which make screening for offspring with incorporated genes impractical.
Jiahao Sha et al. [1] bypassed these limitations by using the CRISPR/Cas9 system, a new technique that has been successfully deployed to genetically engineer several species, including mice and rats (see [2] ). The system targets specific DNA sequences in the genome using Cas9 proteins in combination with what are known as single-guide RNAs. The Cas9 proteins generate single-stranded DNA breaks at the location specified by the RNAs.
The researchers injected Cas9 mRNA and single-guide RNAs designed to target three specific genes into one-cell stage embryos of cynomolgus monkeys (Macaca fascicularis). They analyzed the genome of 15 of the resulting embryos, and showed that eight of them had evidence of knockout in two genes simultaneously. The researchers also implanted embryos into female monkeys and examined the first infants born: a pair of twins (the rest of the females are still gestating). They found that two genes, PPARG and RAG1, were deleted in both twins.
The researchers further showed that the CRISPR/Cas9 system did not cause gene loss at sites other than the intended gene target. Such off-target effects have been observed with the system in other animals, and are one potential barrier to using CRISPR/Cas9 in humans. Implantation of the mammalian embryo into the uterus is controlled by a complex molecular snarl of hormones and their effectors. Researchers working in mice have now teased out the molecular processes behind a crucial event that precedes implantation: an increase in vascular permeability of the blood vessels of the endometrium. This change in the lining of the uterus is the classic marker for incipient implantation. The local change in permeability seems to be mediated by the progesterone receptor, which in turn acts through another member of the nuclear receptor family, Nur77/TR3, functioning as a transcription factor.
Progesterone Promotes Vascular Leakage Prior to Implantation
The early embryo has a high metabolism, but no placenta; instead, it obtains nutrients from the blood vessels of the endometrium, which become ''leaky'' near the embryo. In humans, these blood vessels become leaky when progesterone levels peak during the endometrial cycle.
Lauren Goddard et al. show that progesterone has a regulatory role in this process in mice. Knocking out the progesterone receptor in the endothelial cells that line the uterine blood vessels prevented the development of vascular leakage; it also caused impaired implantation, with a 43 percent reduction in the number of implantation sites. Conversely, expressing the progesterone receptor in the endothelial cells in ectopic locations outside the uterus resulted in increased vascular permeability.
Vascular endothelial growth factor (VEGF) in its multiple forms is a major regulator of vascular permeability in a variety of tissues. But it does not seem to be a regulator of this form of vascular leakage early in the implantation stages. Instead, the researchers pinpointed a role for Nur77/TR33, which has recently been shown to destabilize the junctions between endothelial cells, causing leakage. The researchers showed that Nur77/TR33 regulates expression of proteins at the cell junctions in blood vessels of the endometrium, including PECAM-1, VE-cadherin, and claudin-5. VEGF activity kicks in during later events of implantation, where it is known to be involved in functions such as vascular remodeling during embryo attachment.
Progesterone is known to regulate many of the genes necessary for uterine receptivity and implantation. The new findings add another trick to its repertoire, showing that it induces a transcriptional program via Nur77/Tr3 that affects the expression of adhesion proteins at cell junctions in the blood vessels. The result is increased vascular permeability. The findings may explain why users of long-term, progestin-only contraceptives can experience abnormal endometrial bleeding. The cells of female embryos wait to differentiate until one of their X chromosomes is inactivated, according to new findings in mouse embryos and embryonic stem cells. X-chromosome inactivation allows the cells to exit the pluripotent state and continue development.
X-chromosome inactivation is known to occur through upregulation of the noncoding RNA Xist on one X chromosome, which is then silenced. Previous studies have also uncovered a role for pluripotency transcription factors, such as Oct4 and Nanog, which are present in the very early, undifferentiated embryo and in embryonic stem cells. Such factors have been shown to repress Xist expression. As the abundance of these pluripotency factors wane during early development, X-chromosome inactivation can be initiated.
Edda Schulz et al. now show how X chromosomes in turn influence pluripotency. When active in pairs, the X chromosomes directly interfere with differentiation-only when one X is properly inactivated are cells able to complete the exit from the pluripotent state. The researchers show that two active X chromosomes regulate three molecular pathways known to be involved in stabilizing the pluripotent state: the MAPK and Gsk3 signaling pathways are inhibited, while the Akt pathway is stimulated.
The researchers examined embryonic stem cells with different numbers of X chromosomes, inactivated at different stages. They looked at XO cells (where the second X chromosome is absent), XX cells, and XX cells in which X-chromosome inactivation is blocked or precociously initiated. These experiments, along with supporting in vivo studies, showed that MAPK signaling turns on only upon X-chromosome inactivation. MAPK signaling in turn seems to repress pluripotency factors, in part by turning on enzymes that deposit DNA methylation.
The findings may explain longstanding observations that female embryos grow more slowly than male embryos during the early stages. Perhaps the embryo is waiting until being given the ''all clear'' that an X chromosome has been properly inactivated. Wielding a confocal microscope and a new technique to culture embryos, researchers have scrutinized the developmental events in the embryo as it implants into the uterus. The new findings overturn textbook descriptions of this previously poorly understood stage of embryogenesis.
Prior to implantation, the epiblast cells-destined to become the embryo proper-consist of an unformed ball of cells. As the embryo implants, it elongates, forming a cup-shaped structure with an internal lumen (Fig. 1) . Previous studies have suggested that this lumen forms through cavitation, a process involving apoptosis. Those studies emerged from observations of embryoid bodies, which are formed from aggregates of embryonic stem cells or embryonal carcinomal cells. But this approach has limitations; for instance, embryoid bodies fail to form the same organized structures of the embryo, with its distinct cell types (i.e., epiblast, trophoblast, and primitive endoderm).
In the new study, Ivan Bedzhov and Magdalena Zernicka-Goetz deployed a new system they developed for visualizing this stage of development. The system involves improvements in culture medium and embryo substrate that allow time-lapse live imaging of embryos during their developmental trajectory. They supplemented these studies with experiments on embryos removed from mice and with observations from embryonic stem cells grown in their system.
The researchers found that apoptosis does not occur during the process of lumen formation. Instead, the lumen forms through a hollowing process in which cells separate to form a cavity. The researchers reported that epiblast cells transform from an unformed ball of cells into a rosette-like structure (Fig. 2) . The lumen begins to form at the center of this structure as the apical membranes of the cells separate.
The researchers uncovered some of the molecules involved in this process, showing how proteins typically associated with apical membranes, such as Par-6, accumulate at the center of the rosette and the growing lumen. The cells seem to be pried apart by highly negatively charged proteins at the apical membrane that repel each other-a mechanism that is deployed during lumen formation in other developmental processes. All of these events seem to be triggered by integrin-mediated signaling at the basal membrane, which is in contact with an extracelluar matrix secreted by extra-embryonic cells that surround the epiblast. The researchers propose that proteins in the extracellular matrix instruct the epiblast cells to polarize.
In the future, the new system will allow researchers to delve even deeper into this crucial developmental transition as the embryo loses its independence and latches itself to the mother. 
